X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) CEO Paula Ragan sold 31,897 shares of the business's stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $0.56, for a total transaction of $17,862.32. Following the completion of the sale, the chief executive officer now owns 1,025,816 shares in the company, valued at $574,456.96. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Paula Ragan also recently made the following trade(s):
- On Monday, October 7th, Paula Ragan sold 239,436 shares of X4 Pharmaceuticals stock. The shares were sold at an average price of $0.55, for a total transaction of $131,689.80.
X4 Pharmaceuticals Trading Down 4.3 %
Shares of NASDAQ:XFOR opened at $0.53 on Thursday. The company has a market capitalization of $89.51 million, a PE ratio of -0.76 and a beta of 0.36. The company has a current ratio of 6.07, a quick ratio of 6.04 and a debt-to-equity ratio of 0.79. X4 Pharmaceuticals, Inc. has a 12-month low of $0.47 and a 12-month high of $1.60. The business's fifty day simple moving average is $0.66 and its 200-day simple moving average is $0.86.
Musk’s new company could top a trillion?
From Paradigm Press | Ad
The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix…
Just released the details on what he’s calling Elon’s Project X-9840.
Click here to see the details because there’s not much time to prepare.
X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.03). The business had revenue of $0.56 million for the quarter, compared to analyst estimates of $52.98 million. During the same period in the previous year, the company earned ($0.33) EPS. As a group, equities research analysts predict that X4 Pharmaceuticals, Inc. will post -0.65 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright restated a "buy" rating and issued a $5.00 price target on shares of X4 Pharmaceuticals in a report on Friday, June 28th.
Get Our Latest Report on XFOR
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in XFOR. K2 Principal Fund L.P. purchased a new stake in shares of X4 Pharmaceuticals during the second quarter valued at $284,000. AQR Capital Management LLC lifted its holdings in shares of X4 Pharmaceuticals by 1,080.3% during the second quarter. AQR Capital Management LLC now owns 424,042 shares of the company's stock worth $246,000 after purchasing an additional 388,115 shares during the period. Bank of New York Mellon Corp raised its position in X4 Pharmaceuticals by 39.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 469,372 shares of the company's stock worth $272,000 after buying an additional 133,398 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of X4 Pharmaceuticals in the 2nd quarter valued at $65,000. Finally, Ensign Peak Advisors Inc lifted its position in X4 Pharmaceuticals by 4.6% during the second quarter. Ensign Peak Advisors Inc now owns 2,546,458 shares of the company's stock valued at $1,477,000 after purchasing an additional 111,032 shares during the period. Hedge funds and other institutional investors own 72.03% of the company's stock.
X4 Pharmaceuticals Company Profile
(
Get Free Report)
X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
